<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37282346</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Glucose-6-Phosphate Dehydrogenase Deficiency and Coronavirus Disease 2019.</ArticleTitle><Pagination><StartPage>972</StartPage><EndPage>975</EndPage><MedlinePgn>972-975</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciad348</ELocationID><Abstract><AbstractText>In this cohort study conducted in a national healthcare organization in Israel, we found that individuals with glucose-6-phosphate dehydrogenase deficiency had an increased risk of coronavirus disease 2019 (COVID-19) infection and severity, with higher rates of hospitalization and diagnosed long COVID.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Israel</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4389-8896</Identifier><AffiliationInfo><Affiliation>Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berkovitch</LastName><ForeName>Matitiahu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Pharmacology and Toxicology Unit, Shamir Medical Center, Zerifin, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merzon</LastName><ForeName>Eugene</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Adelson School of Medicine, Ariel University, Ariel, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golan-Cohen</LastName><ForeName>Avivit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Ilan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruppin</LastName><ForeName>Eytan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Cancer Data Science Laboratory, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinker</LastName><ForeName>Shlomo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magen</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Leumit Research Institute and Department of Family Medicine, Leumit Health Services, Tel Aviv-Yafo, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine A Department, Assuta Ashdod University Hospital Faculty of Health Sciences, Ben-Gurion University, Beer-Sheba, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.1.1.49</RegistryNumber><NameOfSubstance UI="D005954">Glucosephosphate Dehydrogenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005954" MajorTopicYN="Y">Glucosephosphate Dehydrogenase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005955" MajorTopicYN="Y">Glucosephosphate Dehydrogenase Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">G6PD deficiency</Keyword><Keyword MajorTopicYN="N">glucose-6-phosphate dehydrogenase</Keyword></KeywordList><CoiStatement>Potential conflicts of interest . E. R. reports financial interests as a cofounder of MedAware and Metabomed, Ltd, and is a divested cofounder and unpaid scientific consultant of Pangea Biomed. E. M. reports honoraria for lectures from Teva, Medisone, and Astra Zeneca; participation on advisory boards for Merck and SK-Pharma; roles as a board member of the Israeli National Diabetes Council and the Israeli Society of ADHD; and a role as a committee member of the Israeli National Dementia Prevention Program. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>7</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37282346</ArticleId><ArticleId IdType="pmc">PMC10552581</ArticleId><ArticleId IdType="doi">10.1093/cid/ciad348</ArticleId><ArticleId IdType="pii">7191288</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cappellini M, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18177777</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami-Far Z, Ghadiri K, Rostami-Far M, Shaveisi-Zadeh F, Amiri A, Rahimian Zarif B. Glucose-6-phosphate dehydrogenase deficiency (G6PD) as a risk factor of male neonatal sepsis. J Med Life 2016; 9:34&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5152609</ArticleId><ArticleId IdType="pubmed">27974910</ArticleId></ArticleIdList></Reference><Reference><Citation>Buinitskaya Y, Gurinovich R, Wlodaver CG, Kastsiuchenka S. Centrality of G6PD in COVID-19: the biochemical rationale and clinical implications. Front Med (Lausanne) 2020; 7:584112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7643021</ArticleId><ArticleId IdType="pubmed">33195336</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsea SH, Razjouyan J, Lee KM, Lynch JA, Martini S, Pandit LM. Association of glucose-6-phosphate dehydrogenase deficiency with outcomes in US veterans with COVID-19. JAMA Netw Open 2023; 6:e235626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10061239</ArticleId><ArticleId IdType="pubmed">36988953</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnasa E, Perzon O, Klinger A, Ezkoria T, Fischer M. Glucose-6-phosphate dehydrogenase deficiency and COVID-19 mortality, ICU admission, and length of hospitalization. Isr Med Assoc J 2023; 25:88&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">36841974</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H-C, Cheng M-L, Ho H-Y, Tsun-Yee Chiu D. The microbicidal and cytoregulatory roles of NADPH oxidases. Microbes Infect 2011; 13:109&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20971207</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeem A, Al-Harbi NO, Ahmad SF, Ibrahim KE, Siddiqui N, Al-Harbi MM. Glucose-6-phosphate dehydrogenase inhibition attenuates acute lung injury through reduction in NADPH oxidase-derived reactive oxygen species. Clin Exp Immunol 2018; 191:279&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801495</ArticleId><ArticleId IdType="pubmed">29277898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh Y-T, Lin M-H, Ho H-Y, Chen L-C, Chen C-C, Shu J-C. Glucose-6-phosphate dehydrogenase (G6PD)-deficient epithelial cells are less tolerant to infection by Staphylococcus aureus. PLoS One 2013; 8:e79566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3817128</ArticleId><ArticleId IdType="pubmed">24223971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y-H, Chiu D, Lin H-R, Tang H-Y, Cheng M-L, Ho H-Y. Glucose-6-phosphate dehydrogenase enhances antiviral response through downregulation of NADPH sensor HSCARG and upregulation of NF-&#x3ba;B signaling. Viruses 2015; 7:6689&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690889</ArticleId><ArticleId IdType="pubmed">26694452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna F, Bonatesta RR, Frongia B, et al. . Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects. J Vasc Res 2007; 44:253&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361089</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bruggen R. Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 2002; 100:1026&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H-R, Wu Y-H, Yen W-C, Yang C-M, Chiu DT-Y. Diminished COX-2/PGE2-mediated antiviral response due to impaired NOX/MAPK signaling in G6PD-knockdown lung epithelial cells. PLoS One 2016; 11:e0153462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4838297</ArticleId><ArticleId IdType="pubmed">27097228</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen W-C, Wu Y-H, Wu C-C, et al. . Impaired inflammasome activation and bacterial clearance in G6PD deficiency due to defective NOX/p38 MAPK/AP-1 redox signaling. Redox Biol 2020; 28:101363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6854078</ArticleId><ArticleId IdType="pubmed">31707353</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal A, Mukherjee S, Dar W, et al. . G6PD deficiency: imbalance of functional dichotomy contributing to the severity of COVID-19. Future Microbiol 2022; 17:1161&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9332910</ArticleId><ArticleId IdType="pubmed">35880537</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>